NCT05633771 - Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting | Biotech Hunter

Enrollment

562

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

December 31, 2026

Conditions

Inflammatory Bowel Disease

Interventions

OTHER

Hyrimoz

There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.

Trial Locations (8)

RECRUITING

Sandoz Investigational Site Belgium, Bonheiden

RECRUITING

Sandoz Investigational Site Belgium, Brussels

RECRUITING

Sandoz Investigational Site France, Auxerre

RECRUITING

Sandoz Investigational Site France, Clichy

RECRUITING

Sandoz Investigational Site France, Nîmes

RECRUITING

Sandoz Investigational Site France, Rennes

RECRUITING

Sandoz Investigational Site France, Toulouse

RECRUITING

Sandoz Investigational Site France, Troyes